Oncology Clinical Trial Finder
Breast Cancer

Completed • Phase O • Stage 0, I, II, III, IV • Post-Menopausal • Interventional

The following is imported from ClinicalTrials.gov:

3D Ultrasound Microvessel Imaging for Breast Masses

This early phase I trial studies how well 3D ultrasound microvessel imaging works for the diagnosis of breast mass. The 3D ultrasound microvessel imaging technology demonstrates significantly increased vessel detection sensitivity over conventional doppler methods without the need of using contrast agents. This study may improve cancer diagnosis and reduce unnecessary biopsy on benign tumors.

PRIMARY OBJECTIVES: I. Optimization of imaging protocol for this new ultrasound technology. II. Investigate the diagnostic performance of the new ultrasound technology using clinically indicated biopsy as the reference standard. OUTLINE: Patients undergo 3 dimensional (D) ultrasound microvessel imaging over 45 minutes. Patients' medical records are reviewed.

Breast Cancer

Study Design
Study type:


Estimated enrollment:

50 participant

Actual study start date:

August 19, 2021

Eligibility Criteria
Ages eligible for study:

18 - 999

Sexes eligible for study:


Arms and Intervention
  • Electronic Health Record Review

  • Ultrasound Microvessel Imaging

Inclusion criteria
  • women with solid breast lesion who are scheduled for a clinically indicated ultrasound-guided biopsy.

  • lesion size of 3 mm or larger.

  • age 18 or greater.

Exclusion criteria
  • women with previous breast surgery or breast implant.

  • lacking the capacity to consent.

  • women who are pregnant or lactating.

  • women who are receiving cancer therapy such as chemotherapy or radiation therapy.

Trial Information at Site
Last Updated:
Trial Information
ClinicalTrial.gov ID:


Estimated Enrollment:


Last Updated:


Principal Investigator

Shigao Chen, Ph.D.

Trial Sponsor

Mayo Clinic

Study Location (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States


© 2024 Outcomes4Me Inc. All rights reserved.